| Primary Site |
Sponsor/Study ID
NTC#
|
Protocol Description |
Eligibility |
Recurrent GBM
(Glioblastoma)
|
ECOG-ACRIN
EAF-151
NCT03115333
|
Change in Relative Cerebral Blood Volume as a Biomarker for Early Response
to Bevacizumab in Patients with Recurrent Glioblastoma |
- Histologically proven intracranial glioblastoma or gliosarcoma at initial surgery
- Karnofsky performance status >= 70
- Progression of disease assessed by Revised Assessment in Neuro-Oncology
(RANO) criteria
- Patient must not have been treated previously with immunotherapies (vaccines,
checkpoint inhibitors, T-cells)
- Intratumoral hemorrhage as seen MRI may preclude inclusion
- Progressive enhancement on MRI
- Patients must be able to tolerate brain MRI scans with dynamic intravenous
gadolinium-based contrast agent injections
- Patient must be scheduled to receive treatment with a standard dose regimen
of bevacizumab
|
| Anaplastic Glioma or Low Grade Glioma |
National Cancer Institute/Alliance
N0577
NCT00887146
|
Phase III Intergroup Study of Temozolomide Alone versus Radiotherapy with
Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant
PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma
or Low Grade Glioma |
- ECOG PS: 0, 1 or 2
- Newly diagnosed and ≤ 3 months from surgical diagnosis
- Histological confirmation of anaplastic glioma or low grade glioma
- Surgery (partial or gross total resection or biopsy) performed ≥ 2 weeks
prior to registration with recovering from effects of surgery.
- Tumor must show 1p/19q codeletion
|
| Meningioma Grade II |
National Cancer Institute
NRG-BN003
NCT03180268
|
Phase III Trial of Observation versus Irradiation for a Gross Totally Resected
grade II Meningioma |
- Newly diagnosed unifocal intracranial meningioma, gross totally resection
and histologically confirmed Grade II
- GTR must be confirmed on post-operative imaging following the most recent surgery
- Post-operative Zubrod performance status 0-1
|
| Brain Tumor |
State of Florida
FCBTR
NCT00811148
|
Florida Center for Brain Tumor Research |
- Adults scheduled to undergo brain surgery to remove tumor tissue
|
| High grade glioma Tissue collection study |
Scripps
1R01CA229737-07
No NCT #
|
Clinical Translation of Precision Medicine Testing Utilizing 3 Dimensional
Primary Tumor Cell Culture |
- Patients scheduled to have surgery for removal of brain tumor.
- Age: 18 years and older.
|
| Leptomeningeal disease registry |
Penn State Registry
No NCT #
|
NeMeRe, a Multi-Institutional Retrospective and Prospective Registry of
Neoplastic Meningitis in Adults/td> |
- Adults 18 years and older diagnosed and treated with neoplastic meningitis.
|
| SCLC |
NRG Oncology
NRG-CC003
NCT02635009
|
Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With
or Without Hippocampal Avoidance for Small Cell Lung Cancer
Effective 5/28/2020 - enrollment temporarily closed.
|
- High-grade neuroendocrine carcinoma or combined SCLC and NSCLC is permitted.
- Prior to chemotherapy +/- thoracic radiotherapy, patients must be defined
as limited-stage or extensive-stage SCLC after clinical staging evaluation.
- Radiographic partial or complete response to chemotherapy in at least one
disease site
- Patients must have a baseline raw score greater than 2 on the HVLT-R Delayed
Recall, as determined by central assessment
- No Radiographic evidence of CNS metastases
- Concurrent atezolizumab permitted with PCI
|
| Brain Metastases |
Alliance
A071701
NCT03994796
|
Genetic Testing in Guiding Treatment for Patients with Brain Metastases |
- Histologically confirmed metastatic disease to the brain from any solid tumor.
-
New or progressive brain metastases defined as any one of the following:
- Untreated measurable lesions in patients who have received surgery and/or
SRS to one or more other lesions.
- Residual or progressive lesions after surgery if asymptomatic.
- Patients who have had prior WBRT and.or SRS and then whose lesions have
progressed by BM-RANO criteria or there are new lesions.
- Patients who have not previously been treated with cranial radiation must
be asymptomatic or neurologically stable from their CNS metastases.
- Ability to obtain MRIs
- Tissue available for sequencing (any brain metastasis tissue and extracranial
site from any prior resection or biopsy).
|
| Low to Intermedium Grade Gliomas |
NRG Oncology
NRG-BN005
NCT03180502
|
Randomized Phase II Trial of Photon Therapy for Cognitive Preservation
in Patients with IDH Mutant, Low to Intermediate Grade Gliomas |
- Grade II and III gliomas IDH mutant.
- Age 18 and over.
- Trial is open to both genders.
- Trial is open to English and French speaking subjects.
|
| Brain Metastases |
Alliance
A071801
NCT04114981
|
Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery
(SRS) Compared with Fractionated SRS (FSRS) for Resected Metastatic Brain Disease |
- Resected brain metastasis must be non-CNS primary site
- ≤3 unresected brain metastases at the time of screening
- Unresected lesions must measure <4.0cm in size
- One brain metastasis must be completely resected ≤30 days prior to registration
- Resected brain metastasis must measure ≥2 cm
- Resection cavity must measure <5.0 cm
|
| Recurrent Glioblastoma |
University of Florida
201600074
NCT02663271
|
TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma |
- Histogically confirmed GBM, WHO grade IV. GBM variants and secondary GBM
are allowed in any recurrence (including multiple) and have been treated
with radiation and chemotherapy.
- Unequivocal evidence of tumor progression during prior bevacizumab treatment
per RANO criteria.
- Patient is a candidate for, and agrees to proceed with bevacizumab treatment.
- Male or female at least 22 years of age or older.
- Karnofsky Performance scale (KPS) ≥ 60%.
|
| Brain metastases (5 - 15) |
Canadian Clinical Trial Group (CCTG)
CE.7
NCT03550391
|
A Phase III Trial of Stereotactic Radiosurgery Compared with Hippocampal-Avoidant
Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5-15 Brain Metastases |
- 5 or more brain metastases.
- Cytological or histological diagnosis of non-hematopoietic malignancy.
- Largest metastasis must measure <2.5 cm in maximal diameter.
- Site must be able to treat with either Gamma Knife, Cyberknife, or a linear-accelerator-based
radiosurgery system.
|